Pyxis Oncology, Inc. Cost of Revenue
Pyxis Oncology, Inc. (PYXS) reported Cost of Revenue of $2.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-03-23
- Pyxis Oncology, Inc. cost of revenue for the quarter ending 2024-12-31 was $0.00.
- Pyxis Oncology, Inc. cost of revenue for the quarter ending 2024-09-30 was $0.00.
- Pyxis Oncology, Inc. cost of revenue for the quarter ending 2024-06-30 was $0.00.
- Pyxis Oncology, Inc. cost of revenue for the quarter ending 2024-03-31 was $475.00K.
- Pyxis Oncology, Inc. cost of revenue for fiscal 2025 was $2.39M, a 402.74% increase from fiscal 2024.
- Pyxis Oncology, Inc. cost of revenue for fiscal 2024 was $475.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.39M 10-K · filed 2026-03-23 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $475.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $475.00K 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $475.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $475.00K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |